ProShare Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-32,556
| Closed | -$702K | – | 1881 |
|
|
2025
Q4 | $702K | Buy |
32,556
+13,822
| +74% | +$268K | ﹤0.01% | 956 |
|
|
2025
Q3 | $286K | Sell |
18,734
-3,199
| -15% | -$41.6K | ﹤0.01% | 1466 |
|
|
2025
Q2 | $194K | Sell |
21,933
-2,421
| -10% | -$21.3K | ﹤0.01% | 1732 |
|
|
2025
Q1 | $191K | Sell |
24,354
-6,238
| -20% | -$52.2K | ﹤0.01% | 1704 |
|
|
2024
Q4 | $322K | Buy |
30,592
+7,433
| +32% | +$90.3K | ﹤0.01% | 1577 |
|
|
2024
Q3 | $304K | Buy |
+23,159
| New | +$353K | ﹤0.01% | 1452 |
|
|
2021
Q4 | – | Sell |
-12,477
| Closed | -$122K | – | 2340 |
|
|
2021
Q3 | $122K | Buy |
12,477
+1,983
| +19% | +$15.6K | ﹤0.01% | 1883 |
|
|
2021
Q2 | $71K | Buy |
+10,494
| New | +$83.3K | ﹤0.01% | 2330 |
|
|
2018
Q4 | – | Sell |
-17,087
| Closed | -$75K | – | 1587 |
|
|
2018
Q3 | $75K | Sell |
17,087
-484
| -3% | -$2.61K | ﹤0.01% | 1702 |
|
|
2018
Q2 | $108K | Sell |
17,571
-1,482
| -8% | -$10.4K | ﹤0.01% | 1702 |
|
|
2018
Q1 | $139K | Sell |
19,053
-3,085
| -14% | -$27.1K | ﹤0.01% | 1599 |
|
|
2017
Q4 | $182K | Sell |
22,138
-693
| -3% | -$6.5K | ﹤0.01% | 1664 |
|
|
2017
Q3 | $240K | Buy |
22,831
+2,078
| +10% | +$19.8K | ﹤0.01% | 1219 |
|
|
2017
Q2 | $229K | Sell |
20,753
-826
| -4% | -$8.29K | ﹤0.01% | 1285 |
|
|
2017
Q1 | $209K | Sell |
21,579
-5,078
| -19% | -$50.8K | ﹤0.01% | 1431 |
|
|
2016
Q4 | $277K | Buy |
26,657
+1,218
| +5% | +$13.4K | ﹤0.01% | 1421 |
|
|
2016
Q3 | $315K | Sell |
25,439
-4,518
| -15% | -$59K | ﹤0.01% | 1134 |
|
|
2016
Q2 | $322K | Buy |
29,957
+171
| +0.6% | +$1.82K | ﹤0.01% | 1171 |
|
|
2016
Q1 | $329K | Sell |
29,786
-2,560
| -8% | -$25.4K | ﹤0.01% | 1169 |
|
|
2015
Q4 | $395K | Buy |
32,346
+2,162
| +7% | +$33.7K | ﹤0.01% | 1152 |
|
|
2015
Q3 | $492K | Sell |
30,184
-1,186
| -4% | -$26.1K | 0.01% | 942 |
|
|
2015
Q2 | $665K | Sell |
31,370
-34
| -0.1% | -$610 | 0.01% | 969 |
|
|
2015
Q1 | $565K | Buy |
31,404
+6,330
| +25% | +$99.1K | 0.01% | 1117 |
|
|
2014
Q4 | $430K | Buy |
+25,074
| New | +$358K | 0.01% | 1281 |
|
Other funds holding AVDL
ProShare Advisors's AVDL Position: Q1 2026 in Review
ProShare Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 32,556 shares — an estimated $702K sold.
ProShare Advisors first reported a position in AVDL in Q4 2014 and held it in 24 quarters. The position peaked at $702K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- ProShare Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- ProShare Advisors sold 32,556 Avadel Pharmaceuticals shares in Q1 2026, an estimated $702K.
- ProShare Advisors first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 24 quarters.
- ProShare Advisors's Avadel Pharmaceuticals position peaked at $702K in Q4 2025.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.